Objective
Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough
blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling
and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart
Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of
total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF,
whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest
indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’
disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during
patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed through a minimally
invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via
inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which
synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/red
color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’
prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage
glucose levels in diabetes.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine endocrinology diabetes
- medical and health sciences clinical medicine cardiology
- medical and health sciences medical biotechnology implants
- medical and health sciences clinical medicine anaesthesiology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
TEL AVIV JAFFA
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.